Our Team

We have built a team with deep expertise in ADC development.

Hui Li, Ph.D

President and CEO

Hui Li, Ph.D. is President and CEO of Adcentrx Therapeutics. Dr. Li has over 20 years of drug discovery and business development experience in the biotech and pharmaceutical industry. Prior to founding Adcentrx in 2021, he was the CEO of Levena Biopharma, a subsidiary of Sorrento Therapeutics, focusing on antibody-drug conjugate (ADC) development. He also served as SVP of Business Development and General Manager of China Operations at Sorrento Therapeutics. During his time at Levena, he was responsible for developing a portfolio of site-specific ADC products and establishing a GMP production site to support clinical development of both internal and external ADC programs. Before Levena, he served as Executive Director of Business Development at PPD and Head of Business Development at its pre-clinical division BioDuro. Prior to joining PPD, he spent 10 years at Pfizer Global Research & Development, where he led several programs in the areas of oncology, diabetes, antiviral, and ophthalmology, which successfully progressed into clinical development. Dr. Li received his B.S. in Chemistry from Peking University and his Ph.D. in Organic Chemistry from University of California, San Diego.

Hui Li, Ph.D

Founder, President & CEO

Hui Li, Ph.D

President and CEO

Hui Li, Ph.D. is President and CEO of Adcentrx Therapeutics. Dr. Li has over 20 years of drug discovery and business development experience in the biotech and pharmaceutical industry. Prior to founding Adcentrx in 2021, he was the CEO of Levena Biopharma, a subsidiary of Sorrento Therapeutics, focusing on antibody-drug conjugate (ADC) development. He also served as SVP of Business Development and General Manager of China Operations at Sorrento Therapeutics. During his time at Levena, he was responsible for developing a portfolio of site-specific ADC products and establishing a GMP production site to support clinical development of both internal and external ADC programs. Before Levena, he served as Executive Director of Business Development at PPD and Head of Business Development at its pre-clinical division BioDuro.

Prior to joining PPD, he spent 10 years at Pfizer Global Research & Development, where he led several programs in the areas of oncology, diabetes, antiviral, and ophthalmology, which successfully progressed into clinical development.

Dr. Li received his B.S. in Chemistry from Peking University and his Ph.D. in Organic Chemistry from University of California, San Diego.

Pia Challita-Eid, Ph.D

Chief Scientific Officer

Pia Challita-Eid, Ph.D. is Chief Scientific Officer at Adcentrx Therapeutics and serves as the Head of Research. She brings over 20 years of experience in the biotechnology industry, contributing to the discovery and progression into the clinic of over 12 drug candidates including the FDA-approved product Padcev™. Prior to joining Adcentrx in 2021, she served as Vice President, ADC Research at Levena Biopharm, a Sorrento Therapeutics company, where she led the preclinical ADC pipeline. Previously, she held various positions with increasing responsibilities at Agensys Inc., an affiliate of Astellas Pharmaceuticals Inc., supporting the company’s pipeline portfolio including ADCs and Immuno-oncology candidates. She led the molecular oncology initiatives, target identification and selection, therapeutic antibody discovery and engineering activities. Dr. Challita-Eid began her career in academia as a faculty member at the University of Rochester Cancer Center focusing on cancer immunotherapy. Dr. Challita-Eid received her B.S. and M.S. in Biology from the American University of Beirut, and her Ph.D. in Microbiology from the University of Southern California. She conducted her post-doctoral training at the University of California, Los Angeles.

Pia Challita-Eid, Ph.D

Chief Scientific Officer

Pia Challita-Eid, Ph.D

Chief Scientific Officer

Pia Challita-Eid, Ph.D. is Chief Scientific Officer at Adcentrx Therapeutics and serves as the Head of Research. She brings over 20 years of experience in the biotechnology industry, contributing to the discovery and progression into the clinic of over 12 drug candidates including the FDA-approved product Padcev™.

Prior to joining Adcentrx in 2021, she served as Vice President, ADC Research at Levena Biopharm, a Sorrento Therapeutics company, where she led the preclinical ADC pipeline. Previously, she held various positions with increasing responsibilities at Agensys Inc., an affiliate of Astellas Pharmaceuticals Inc., supporting the company’s pipeline portfolio including ADCs and Immuno-oncology candidates. She led the molecular oncology initiatives, target identification and selection, therapeutic antibody discovery and engineering activities. Dr. Challita-Eid began her career in academia as a faculty member at the University of Rochester Cancer Center focusing on cancer immunotherapy.

Dr. Challita-Eid received her B.S. and M.S. in Biology from the American University of Beirut, and her Ph.D. in Microbiology from the University of Southern California. She conducted her post-doctoral training at the University of California, Los Angeles.

Meng Jiang

Chief Financial Officer

Meng Jiang joined Adcentrx as Chief Financial Officer in March 2024. Ms. Jiang has over 20 years of finance, investment banking and M&A experience.
Prior to joining Adcentrx, Ms. Jiang served as Senior Managing Director and most recently as Head of Venture at CBC Group, which she co-founded and where she led the incubation of Adcentrx and number of other companies while leading CBC’s therapeutics investments. Prior to CBC Group, Ms. Jiang held additional roles at Far East Horizon’s Investments Group, ARC China, BDA and UBS Investment Bank in New York.
Ms. Jiang graduated with Honors in Economics and Political Science from Wellesley College.

Meng Jiang

Chief Financial Officer

Meng Jiang

Chief Financial Officer

Meng Jiang joined Adcentrx as Chief Financial Officer in March 2024. Ms. Jiang has over 20 years of finance, investment banking and M&A experience.

Prior to joining Adcentrx, Ms. Jiang served as Senior Managing Director and most recently as Head of Venture at CBC Group, which she co-founded and where she led the incubation of Adcentrx and number of other companies while leading CBC’s therapeutics investments. Prior to CBC Group, Ms. Jiang held additional roles at Far East Horizon’s Investments Group, ARC China, BDA and UBS Investment Bank in New York.

Ms. Jiang graduated with Honors in Economics and Political Science from Wellesley College.

Maojun Guo, Ph.D

Senior Vice President, Research

Maojun Guo, Ph.D. is Senior Vice President, Research at Adcentrx Therapeutics. Dr. Guo has more than 25 years of drug development experience across both academia and industry.

Prior to joining Adcentrx in 2021, Dr. Guo held Vice President positions at Gear Pharma, Levena Biopharma and Shanghai Alputon PharmTech where he was responsible for the chemistry of internal and external projects, which included discovery, IND-enabling CMC work, GMP production and ADC platform development. Dr. Guo has also held roles at Lundbeck, ArQule and Hybridon where he participated in programs in the areas of antisense oligonucleotides, combinatorial chemistry, and CNS, and was involved with Lundbeck’s major depressive disorder Trintellix/Brintellix (vortioxetine) program that successfully launched in 2013. Before entering the BioPharma industry, Dr. Guo was a researcher at Sheffield University and the MRC Laboratory of Molecular Biology at Cambridge University.

Dr. Guo earned his B.S. in Analytical Chemistry from Wuhan University and his Ph.D. in Medicinal Chemistry from Peking University Medical School.

Maojun Guo, Ph.D

Senior Vice President, Research

Maojun Guo, Ph.D

Senior Vice President, Research

Maojun Guo, Ph.D. is Senior Vice President, Research at Adcentrx Therapeutics. Dr. Guo has more than 25 years of drug development experience across both academia and industry.

Prior to joining Adcentrx in 2021, Dr. Guo held Vice President positions at Gear Pharma, Levena Biopharma and Shanghai Alputon PharmTech where he was responsible for the chemistry of internal and external projects, which included discovery, IND-enabling CMC work, GMP production and ADC platform development. Dr. Guo has also held roles at Lundbeck, ArQule and Hybridon where he participated in programs in the areas of antisense oligonucleotides, combinatorial chemistry, and CNS, and was involved with Lundbeck’s major depressive disorder Trintellix/Brintellix (vortioxetine) program that successfully launched in 2013. Before entering the BioPharma industry, Dr. Guo was a researcher at Sheffield University and the MRC Laboratory of Molecular Biology at Cambridge University.

Dr. Guo earned his B.S. in Analytical Chemistry from Wuhan University and his Ph.D. in Medicinal Chemistry from Peking University Medical School.

Alex Chu-Kung, Ph.D

Vice President, CMC

Alexander Chu-Kung, Ph.D. is Vice President, CMC and the head of development at Adcentrx Therapeutics. Prior to joining Adcentrx in 2021, Dr. Chu-Kung was the Senior Director of Development at Levena Biopharma, a subsidiary of Sorrento Therapeutics where he was responsible for all aspects of process development, cGMP manufacturing and clinical supply of the antibody drug conjugate pipeline.

Before joining Levena Biopharma, Dr. Chu-Kung spent more than decade at AbbVie, most recently as a principal scientist. In this role he oversaw process development, tech transfer, CMO interaction and scale-up for both small molecule and biologic therapeutics.

Dr. Chu-Kung holds a Ph.D. degree in Chemical Engineering from University of California, Santa Barbara and a B.S. degree in chemical engineering from Northwestern University.

Alex Chu-Kung, Ph.D

Vice President, CMC

Alex Chu-Kung, Ph.D

Vice President, CMC

Alexander Chu-Kung, Ph.D. is Vice President, CMC and the head of development at Adcentrx Therapeutics. Prior to joining Adcentrx in 2021, Dr. Chu-Kung was the Senior Director of Development at Levena Biopharma, a subsidiary of Sorrento Therapeutics where he was responsible for all aspects of process development, cGMP manufacturing and clinical supply of the antibody drug conjugate pipeline.

Before joining Levena Biopharma, Dr. Chu-Kung spent more than decade at AbbVie, most recently as a principal scientist. In this role he oversaw process development, tech transfer, CMO interaction and scale-up for both small molecule and biologic therapeutics.

Dr. Chu-Kung holds a Ph.D. degree in Chemical Engineering from University of California, Santa Barbara and a B.S. degree in chemical engineering from Northwestern University.

Andrew Hopkins, M.B.S.

Vice President, Business Development

Andrew Hopkins, M.B.S. is Vice President, Business Development at Adcentrx Therapeutics. He has nearly 20 years of corporate development and strategic planning experience on both the buy- and sell-side. He has completed transactions with over $1 billion in aggregate deal value, including M&A, licensing, collaborations and fund raising. Prior to joining Adcentrx in 2022, he was Senior Director, Business Development at Halozyme Therapeutics, a public biotechnology company focused on enabling platforms for the pharmaceutical industry, where he led the search and evaluation efforts for platform M&A. Previously, Mr. Hopkins held various positions with increasing responsibility at Vical Incorporated where he led the reverse merger with Brickell Bio in 2019 and the licensing of VL-2397 from Astellas in 2015. Mr. Hopkins has additional experience as a management consultant at Campbell Alliance (now Syneos Health) and a pharmaceutical sales representative at Quintiles. Mr. Hopkins holds a B.S. in Microbiology and Biotechnology from the University of Cape Town and a Master of Business and Science from the Keck Graduate Institute of Applied Life Sciences.

Andrew Hopkins, M.B.S.

Vice President, Business Development

Andrew Hopkins, M.B.S.

Vice President, Business Development

Andrew Hopkins, M.B.S. is Vice President, Business Development at Adcentrx Therapeutics. He has nearly 20 years of corporate development and strategic planning experience on both the buy- and sell-side. He has completed transactions with over $1 billion in aggregate deal value, including M&A, licensing, collaborations and fund raising. Prior to joining Adcentrx in 2022, he was Senior Director, Business Development at Halozyme Therapeutics, a public biotechnology company focused on enabling platforms for the pharmaceutical industry, where he led the search and evaluation efforts for platform M&A. Previously, Mr. Hopkins held various positions with increasing responsibility at Vical Incorporated where he led the reverse merger with Brickell Bio in 2019 and the licensing of VL-2397 from Astellas in 2015. Mr. Hopkins has additional experience as a management consultant at Campbell Alliance (now Syneos Health) and a pharmaceutical sales representative at Quintiles. Mr. Hopkins holds a B.S. in Microbiology and Biotechnology from the University of Cape Town and a Master of Business and Science from the Keck Graduate Institute of Applied Life Sciences.

Abraham Fong, M.D., PH.D.

Vice President, Clinical Development

Abraham Fong, M.D., PH.D. is Vice President, Clinical Development at Adcentrx. He has over 8 years of clinical experience across both early and late-stage drug development primarily focused on ADCs and immunotherapeutics. Prior to joining Adcentrx in 2023, Dr. Fong was Executive Medical Director, Clinical Development at ALX Oncology where he led the hematology malignancy program, including strategic planning and oversight of studies with a CD47-inhibitor in AML and MDS, along with early development of a novel antibody conjugate and multiple studies in solid tumors. Before joining ALX Oncology, Dr. Fong held medical director roles at AbbVie and Seattle Genetics, where he oversaw multiple early and late phase ADC studies across both hematologic and solid tumor malignancies. Dr. Fong received his M.D. and Ph.D. degrees from Penn State College of Medicine and a B.S. degree from University of California, Los Angeles. He completed his residency in pediatrics at Lucile Packard Children’s Hospital in Palo Alto, California and fellowship in Hematology-Oncology at Seattle Children’s Hospital and Fred Hutchinson Cancer Research Center in Seattle, Washington, where as a faculty member he conducted research focused on the development of novel therapeutics for pediatric malignancies.

Abraham Fong, M.D., PH.D.

Vice President, Clinical Development

Abraham Fong, M.D., PH.D.

Vice President, Clinical Development

Abraham Fong, M.D., PH.D. is Vice President, Clinical Development at Adcentrx. He has over 8 years of clinical experience across both early and late-stage drug development primarily focused on ADCs and immunotherapeutics.

 

Prior to joining Adcentrx in 2023, Dr. Fong was Executive Medical Director, Clinical Development at ALX Oncology where he led the hematology malignancy program, including strategic planning and oversight of studies with a CD47-inhibitor in AML and MDS, along with early development of a novel antibody conjugate and multiple studies in solid tumors. Before joining ALX Oncology, Dr. Fong held medical director roles at AbbVie and Seattle Genetics, where he oversaw multiple early and late phase ADC studies across both hematologic and solid tumor malignancies.

 

Dr. Fong received his M.D. and Ph.D. degrees from Penn State College of Medicine and a B.S. degree from University of California, Los Angeles. He completed his residency in pediatrics at Lucile Packard Children’s Hospital in Palo Alto, California and fellowship in Hematology-Oncology at Seattle Children’s Hospital and Fred Hutchinson Cancer Research Center in Seattle, Washington, where as a faculty member he conducted research focused on the development of novel therapeutics for pediatric malignancies.

Joseph Shan, M.P.H.

Vice President, Clinical Operations

Joseph Shan, M.P.H. joined Adcentrx as Vice President, Clinical Operations in December 2023. Mr. Shan has close to 30 years of clinical experience in biopharma and medical device companies. Nearly 25 years were focused on clinical development of oncology therapeutics, including radiopharmaceuticals, small molecules, targeted therapy, immunotherapy and cellular therapy. Prior to joining Adcentrx, Mr. Shan served as Executive Director, Clinical Development Operations and Data Management at MEI Pharma, where he oversaw early phase clinical studies of a CDK9 inhibitor in AML and B-cell malignancies and a mitochondrial inhibitor in colorectal cancer. Before MEI Pharma, he held leadership roles at Elevar Therapeutics, Kiadis Pharma (formerly CytoSen Therapeutics) and was VP, Clinical & Regulatory Affairs and a corporate officer of Peregrine Pharmaceuticals for nearly a decade, spearheading development of bavituximab (a novel phosphatidylserine-targeting monoclonal antibody for treatment of solid tumors) from pre-clinical through Phase 3. Mr. Shan received his M.P.H. degree, with emphasis in Epidemiology from George Washington University in Washington D.C. and a B.S. degree in Physiological Sciences from University of California, Los Angeles.

Joseph Shan, M.P.H.

Vice President, Clinical Operations

Joseph Shan, M.P.H.

Vice President, Clinical Operations

Joseph Shan, M.P.H. joined Adcentrx as Vice President, Clinical Operations in December 2023. Mr. Shan has close to 30 years of clinical experience in biopharma and medical device companies. Nearly 25 years were focused on clinical development of oncology therapeutics, including radiopharmaceuticals, small molecules, targeted therapy, immunotherapy and cellular therapy. Prior to joining Adcentrx, Mr. Shan served as Executive Director, Clinical Development Operations and Data Management at MEI Pharma, where he oversaw early phase clinical studies of a CDK9 inhibitor in AML and B-cell malignancies and a mitochondrial inhibitor in colorectal cancer. Before MEI Pharma, he held leadership roles at Elevar Therapeutics, Kiadis Pharma (formerly CytoSen Therapeutics) and was VP, Clinical & Regulatory Affairs and a corporate officer of Peregrine Pharmaceuticals for nearly a decade, spearheading development of bavituximab (a novel phosphatidylserine-targeting monoclonal antibody for treatment of solid tumors) from pre-clinical through Phase 3. Mr. Shan received his M.P.H. degree, with emphasis in Epidemiology from George Washington University in Washington D.C. and a B.S. degree in Physiological Sciences from University of California, Los Angeles.

Queenie Yu, M.M.

Vice President, Clinical Operations, M.M.

Xiaokun “Queenie” Yu joined Adcentrx as Vice President, Clinical Operations in January 2024. Ms. Yu has over 16 years of clinical experience in biopharma companies, primarily focused on oncology therapeutics, including small molecules, targeted therapies, immunotherapies and cancer vaccines. She has deep expertise in global trial management from early phase through late phase clinical development.

Prior to joining Adcentrx, Ms. Yu served as Executive Director, Clinical Operation Head at Abogen where she oversaw cancer vaccine and COVID19 vaccine studies. Before Abogen, Ms. Yu held various leadership roles at Dizal Pharma, most recently as Senior Director, Operation Project Leader, where she oversaw global clinical studies of sunvozertinib, an EGFR exon20 inhibitor in NSCLC patients leading to the 2023 launch of the compound in China. Ms. Yu previously worked as Clinical Development Manager at AstraZeneca where she led key studies for durvalumab + tremelimumab combination studies in bladder cancer across 25 countries, Caprelsa in medullary thyroid cancer in 10 countries, and AZD9291 in China. Ms. Yu additionally worked at Roche as Country Study Manager and Quality&Compliance Manager where she involved in clinical studies in China such as TDM1, Herceptin, Avastin, as well as clinical quality control and training.

Ms. Yu holds a Master in Surgery of TCM from Shanghai University of TCM, and B.S. of Integrated Chinese and Western Medicine from Changchun University of TCM.

Queenie Yu, M.M.

Vice President, Clinical Operations

Queenie Yu, M.M.

Vice President, Clinical Operations

Xiaokun “Queenie” Yu joined Adcentrx as Vice President, Clinical Operations in January 2024. Ms. Yu has over 16 years of clinical experience in biopharma companies, primarily focused on oncology therapeutics, including small molecules, targeted therapies, immunotherapies and cancer vaccines. She has deep expertise in global trial management from early phase through late phase clinical development.

Prior to joining Adcentrx, Ms. Yu served as Executive Director, Clinical Operation Head at Abogen where she oversaw cancer vaccine and COVID19 vaccine studies. Before Abogen, Ms. Yu held various leadership roles at Dizal Pharma, most recently as Senior Director, Operation Project Leader, where she oversaw global clinical studies of sunvozertinib, an EGFR exon20 inhibitor in NSCLC patients leading to the 2023 launch of the compound in China. Ms. Yu previously worked as Clinical Development Manager at AstraZeneca where she led key studies for durvalumab + tremelimumab combination studies in bladder cancer across 25 countries, Caprelsa in medullary thyroid cancer in 10 countries, and AZD9291 in China. Ms. Yu additionally worked at Roche as Country Study Manager and Quality&Compliance Manager where she involved in clinical studies in China such as TDM1, Herceptin, Avastin, as well as clinical quality control and training.

Ms. Yu holds a Master in Surgery of TCM from Shanghai University of TCM, and B.S. of Integrated Chinese and Western Medicine from Changchun University of TCM.